Teva Pharmaceutical Industries Net Change in Long-Term Investments 2010-2024 | TEVA
Teva Pharmaceutical Industries annual/quarterly net change in long-term investments history and growth rate from 2010 to 2024. Net change in long-term investments can be defined as the net cash flows from the sale and purchase of investments with maturities greater than one year.
- Teva Pharmaceutical Industries net change in long-term investments for the quarter ending December 31, 2024 was $-0.031B, a 32.61% decline year-over-year.
- Teva Pharmaceutical Industries net change in long-term investments for the twelve months ending December 31, 2024 was $-0.114B, a 14% increase year-over-year.
- Teva Pharmaceutical Industries annual net change in long-term investments for 2024 was $-0.031B, a 32.61% decline from 2023.
- Teva Pharmaceutical Industries annual net change in long-term investments for 2023 was $-0.046B, a 1633.33% decline from 2022.
- Teva Pharmaceutical Industries annual net change in long-term investments for 2022 was $0.003B, a 97.6% decline from 2021.
Teva Pharmaceutical Industries Annual Net Change in Long-Term Investments
(Millions of US $) |
| 2024 |
$-31 |
| 2023 |
$-46 |
| 2022 |
$3 |
| 2021 |
$125 |
| 2020 |
$-43 |
| 2019 |
$-8 |
| 2018 |
$-119 |
| 2017 |
$-200 |
| 2016 |
$-481 |
| 2015 |
$-2,003 |
| 2014 |
$-324 |
| 2013 |
$-160 |
| 2012 |
$-201 |
| 2011 |
$-217 |
| 2010 |
$-436 |
| 2009 |
$-433 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$17.427B |
$16.544B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
